Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 16; no. 3; pp. 129 - 138
• Main Authors: Berdeja, Jesus, Jagannath, Sundar, Zonder, Jeffrey, Badros, Ashraf, Kaufman, Jonathan L, Manges, Robert, Gupta, Manish, Tendolkar, Amol, Lynch, Mark, Bleickardt, Eric, Paliwal, Prashni, Vij, Ravi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2016
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Creatinine clearance; Cytogenetic Analysis; Dexamethasone - administration & dosage; Dexamethasone - pharmacokinetics; End-stage renal disease; Female; Glomerular filtration rate; Hematology, Oncology and Palliative Medicine; Humans; Kidney Diseases - complications; Kidney Diseases - diagnosis; Kidney Diseases - physiopathology; Kidney Function Tests; Male; Middle Aged; Monoclonal antibody; Multiple Myeloma - complications; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Neoplasm Staging; Retreatment; Severity of Illness Index; SLAMF7; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Thalidomide - pharmacokinetics; Treatment Outcome; End-stage renal disease; SLAMF7; Monoclonal antibody; Creatinine clearance; Glomerular filtration rate
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2015.12.007

Micro-Abstract Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone, is not significantly different between patients with MM with and without renal impairment, suggesting that elotuzumab might be administered without dose adjustment for renal function.